



Curriculum vitae

Mohsen Hemmati-Dinarvand, PhD.

**Department of Biochemistry and Laboratory Medicine
Faculty of Medicine
Kashan University of Medical Sciences**

*Kasha University for Medical Sciences, Faculty of Medicine
Kashan, Iran*

Phone: +989358364998

E-MAILs: Mohsen_h43@yahoo.com

Hemmati-m@kaums.ac.ir

Date of birth & place: *March 17th, 1989, Lorestan/Iran*

Nationality: *Iranian*

Marital status: *Unmarried*

Professional Address: *Department of Biochemistry, Medical School, Kashan University of Medical Sciences, Kashan, Iran*

EDUCATION

Shiraz University of Medical Sciences

Philosophy Doctorate (PhD) in Clinical Biochemistry (Sep 2018- March 2022)

Thesis: The Evaluation of Nitazoxanide Effect on Drug Resistance Reduction in Oxaliplatin-Resistant LS174T Colorectal Cancer.

First Supervisor: Dr. Atefeh Seghatoleslam

Second Supervisor: Dr, Hassan Ahmadvand

Advisor (s): Dr. Fakhraddin Naghibalhossaini & Dr. Zohreh Mostafavi-pour

Tabriz University of Medical Sciences

Master of Science (M.Sc.) in Clinical Biochemistry (Sep 2015-Dec 2017)

Thesis: The study of NOX1, selenium and uric acid concentrations in the serum of patients with Parkinson disease.

Supervisor: Dr. Nasser Samadi

Advisors: Dr. Aliakbar Taheraghdam, Dr. Ali Mota

Research Interests:

- *Clinical biochemistry*
- *Neurobiochemistry*
- *Cancer biology*
- *Cancer drug resistance*
- *Biochemical markers for diagnostic, identification of pharmaceutical effects in Human diseases.*
- *Molecular mechanisms involved in the development of acute and chronic Human disease.*

skills:

- *Primer design*
- *Fluorescence Microscopy- Enzyme Linked Immunosorbent Assay (ELISA)*
- *Atomic Absorption Spectrophotometry (AAS)*
- *Light Spectrophotometry*
- *RT-qPCR method*
- *Western blot method*
- *Cell culture*
- *MTT assay*
- *PCR method*

- *SPSS and graph pad prism analysis*
- *Academic article writing*

Short Courses & Workshops

- *2015, Primer design workshop, Tabriz University of Medical Sciences.*
- *2015, Article Writing Workshop, Tabriz University of Medical Sciences.*
- *2016, Internet Databases training program, Physics Faculty of Tabriz University.*

Publications

- **Mohammadi M**, Fazilat A, Mamalo AS, Ojarudi M, Hemmati-Dinarvand M, Beilankouhi EA, Valilo M. *Correlation of PTEN signaling pathway and miRNA in breast cancer. Molecular Biology Reports.* 2024 Dec;51(1):221.
- Saedi S, Hemmati F, **Hemmati-Dinarvand M**. *The relationship between the stomach and the brain: investigating Helicobacter Pylori infection pathways and its association with Parkinson's disease. Biochemistry and Nutrition in Metabolic Diseases.* 2024 Feb 18;1(1):48-55.

- **Hemmati-Dinarvand M**, Mokhtari H, Alipourfard I, Beyrami Aghbash E, Kheirandish S, Khodadadian A, Seghatoleslam A. *Cancer Drug Resistance Reduction via Co-treatment with Oxaliplatin and Nitazoxanide: Targeting the ABC Transporters*. *Current molecular medicine*. 2023 Oct 1;23(8):834-41.
- Pakravan S, **Hemmati-Dinarvand M**, Moghaddasi M, Fathi J, Nowrouzi-Sohrabi P, Hormozi M. *Hydroxytyrosol's effect on the expression of apoptosis and oxidative stress related genes in BE (2)-C neuroblastoma cell line*. *Gene Reports*. 2023 Jun 1;31:101750.
- Musavi H, Abazari O, Barartabar Z, Kalaki-Jouybari F, **Hemmati-Dinarvand M**, Esmaeili P, Mahjoub S. *The benefits of Vitamin D in the COVID-19 pandemic: biochemical and immunological mechanisms*. *Archives of physiology and biochemistry*. 2023 Mar 4;129(2):354-62.
- Khoshdel Z, Gholijani N, Niknam M, Rahmani N, **Hemmati-Dinarvand M**, Naghibalhossaini F. *Serum Copper and Zinc levels among Iranian vitiligo patients*. *Dermatology practical & conceptual*. 2022 Nov;12(4).
- **Hemmati-Dinarvand M**, Kheirandish S, Khodadadian A, Mostafazadeh M, Seghatoleslam A. *Blockage of Wnt/β-catenin Signaling Pathway in Colorectal Cancer Resistant Cells by Nitazoxanide Effects on Peptidylarginine Deiminases Expression*. *Asian Pacific journal of cancer prevention: APJCP*. 2022 Sep;23(9):3215.

- **Hemmati-Dinarvand M**, Ahmadvand H, Seghatoleslam A. Nitazoxanide and cancer drug resistance: targeting Wnt/β-catenin signaling pathway. *Archives of Medical Research*. 2022 Apr 1;53(3):263-70.
- **Hemmati-Dinarvand M**, Malekshahi A, Afsharifar A. Employment of virus-like particles in vaccines production. *Yafteh*. 2022;23(5).
- Hemmati F, **Hemmati-Dinarvand M**, Karimzade M, Rutkowska D, Eskandari MH, Khanizadeh S, Afsharifar A. Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2. *Biotechnology Letters*. 2022 Jan 1:1-3.
- Saedi S, **Hemmati-Dinarvand M**, Barmaki H, Mokhtari Z, Musavi H, Valilo M, Mota A, Mahjoub S. Serum lipid profile of Parkinson's disease patients: A study from the Northwest of Iran. *Caspian journal of internal medicine*. 2021 Mar;12(2):155.
- Barmaki H, Morovati A, Eydivandi Z, Naleshkenani FJ, Saedi S, Musavi H, Abbasi M, **Hemmati-Dinarvand M**. The association between serum oxidative stress indexes and pathogenesis of Parkinson's disease in the northwest of Iran. *Iranian journal of public health*. 2021 Mar;50(3):606.
- Khodadadian A, Varghaiyan Y, Babakhanzadeh E, Alipourfard I, Haghi-Daredeh S, Ghobadi A, **Hemmati-Dinarvand M**, Talebi M, Ghasemi N. Fertility preservation in women with ovarian cancer: Finding new pathways: A case-control study. *International Journal of Reproductive BioMedicine*. 2021 Feb;19(2):157.

- Fattah A, Amiri F, Mohammadian M, Alipourfard I, Valilo M, Taheraghdam A, **Hemmati-Dinarvand M**. Dysregulation of body antioxidant content is related to initiation and progression of Parkinson's disease. *Neuroscience Letters*. 2020 Sep 25;736:135297.
- Hemmati F, Saedi S, **Hemmati-Dinarvand M**, Zarei M, Seghatoleslam A. Mysterious virus: a review on behavior and treatment approaches of the novel coronavirus, 2019-nCoV. *Archives of Medical Research*. 2020 Jul 1;51(5):375-83.
- Alizadeh-Sani M, Rhim JW, Azizi-Lalabadi M, **Hemmati-Dinarvand M**, Ehsani A. Preparation and characterization of functional sodium caseinate/guar gum/TiO₂/cumin essential oil composite film. *International journal of biological macromolecules*. 2020 Feb 15;145:835-44.
- Ghavami A, Roshanravan N, Nattagh-Eshtivani E, Sharifi S, Arzhang P, Sani MA, **Dinarvand MH**, Shokri A, Ostadrahimi A. The effect of high performance inulin on appetite, energy in-take and anthropometric indices in patient with type 2 diabetes. *Progr. Nutr.*. 2019 Dec 1;21:121-6.
- **Hemmati-Dinarvand M**, Valilo M, Kalantary-Charvadeh A, Sani MA, Kargar R, Safari H, Samadi N. Oxidative stress and Parkinson's disease: conflict of oxidant-antioxidant systems. *Neuroscience Letters*. 2019 Sep 14;709:134296.
- Mota A, **Hemmati-Dinarvand M**, Taheraghdam AA, Nejabati HR, Ahmadi R, Ghasemnejad T, Hasanpour M, Valilo M. Association of Paraoxonase1 (PON1)

Genotypes with the Activity of PON1 in Patients with Parkinson's Disease.

Acta Neurol Taiwan. 2019 Sep 1;28(3):66-74.

- *Kalantary-Charvadeh A, Sanajou D, **Hemmati-Dinarvand M**, Marandi Y, Khojastehfard M, Hajipour H, Mesgari-Abbas M, Roshangar L, Nazari Soltan Ahmad S. Michelolide protects against doxorubicin-induced cardiotoxicity in mice by regulating PI3K/Akt/NF- κ B signaling pathway. Cardiovascular toxicology. 2019 Aug 15;19:297-305.*
- ***Hemmati-Dinarvand M**, Niknam M, Zununi Vahed S, Samadi N. Serum uric acid and albumin are affected by different variables in Parkinson's disease. Neurological Sciences. 2019 Jan;40:187-8.*
- ***Hemmati-Dinarvand M**, Taheraghdam A, Mota A, Vahed SZ, Samadi N. In response to a letter to Editor by Vivek Kumar Garg., et al. on our paper: "Dysregulation of serum NADPH oxidase1 and ferritin levels provides insights into diagnosis of Parkinson's disease". Hemmati-Dinarvand, M., et al. 2017; 50 (18): 1087-1092. Clinical biochemistry. 2018 Jun;56:118-9.*
- *Khodadadian A, **Hemmati-Dinarvand M**, Kalantary-Charvadeh A, Ghobadi A, Mazaheri M. Candidate biomarkers for Parkinson's disease. Biomedicine & Pharmacotherapy. 2018;104:699-704.*
- ***Hemmati-Dinarvand M**, Taheraghdam A, Mota A, Vahed SZ, Samadi N. In response to letter to Editor by Vivek Kumar Garg., et al. on our paper: "Dysregulation of serum NADPH oxidase1 and ferritin levels provides insights*

into diagnosis of Parkinson's disease". Hemmati-Dinarvand, M., et al. 2017; 50 (18):1087-1092. Clin Biochem. 2018 Apr 24. pii: S0009-9120(18)30390-4. doi: 10.1016/j.clinbiochem.2018.04.023. [Epub ahead of print].

- **Hemmati-Dinarvand, M., et al.**, *Dysregulation of serum NADPH oxidase1 and ferritin levels provides insights into diagnosis of Parkinson's disease. Clinical biochemistry, 2017. 50(18): p. 1087-1092.*

Conferences

- ***Poster presentation in 6th basic and clinical neuroscience Congress Iran University of Medical Sciences, Tehran, Iran.***
- ***Poster presentation in 2nd International and 10th National Iranian Neurogenetic Congress Mashhad University of Medical Sciences, Mashhad, Iran.***
- ***Poster presentation in 2nd International and 10th National Iranian Neurogenetic Congress Mashhad University of Medical Sciences, Mashhad, Iran.***

Awards

- ***1st rank of the 10th Kharazmi Youth Festival in the story of writing (2009).***
-